# ZYAK

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zyak

- Industry: Pharmaceuticals
- Headquarters: Tianjin, China
- Website: www.gazobiotech.com
- Total disclosed funding: $36M
- Latest round: Series A (Jul 4, 2019)
- Investors on record: 7

## About

Established in 2001 and based in Tianjin, China, ZYAK is a vaccine developer and manufacturer. It has acquired High-Tech Enterprise Certificate. In July 2019, ZYAK raised a CNY 250 million of series A funding from new investor China Capital Management, Efung Capital, Guoyu Investment, Huaige Capital, National Engineering Research Center of Veterinary Biologics, Shenzhen Kunding Venture Capital Investment    and Shenzhen Qianhai Beizeng Capital Management.

The company is mainly engaged in the research and development, production and sales of human vaccines. Its products include influenza virus subunit vaccines, etc.

The company generates revenue by developing human vaccine such as Influenza virus subunit vaccine.

## Funding rounds

- Series A, Jul 4, 2019, $36M — Efung Capital, China Capital Management, Kunding Venture Capital, Guoyu Investment, Huaige Capital, Shenzhen Qianhai Beizeng Asset Management, National Engineering Research Center of Veterinary Biologics

## Investors

- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series A
- China Capital Management (https://capitalatlas.ai/funds/china-capital-management) — Series A
- Kunding Venture Capital (https://capitalatlas.ai/funds/kunding-venture-capital) — Series A
- Guoyu Investment (https://capitalatlas.ai/funds/guoyu-investment) — Series A
- Huaige Capital (https://capitalatlas.ai/funds/huaige-capital) — Series A
- Shenzhen Qianhai Beizeng Asset Management (https://capitalatlas.ai/funds/shenzhen-qianhai-beizeng-asset-management) — Series A
- National Engineering Research Center of Veterinary Biologics — Series A